

HR 5882

GENE Therapy Payment Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 12, 2020

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Feb 12, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/5882>

Sponsor

Name: Rep. Schrader, Kurt [D-OR-5]

Party: Democratic • **State:** OR • **Chamber:** House

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bera, Ami [D-CA-7]	D · CA		Feb 12, 2020
Rep. Crow, Jason [D-CO-6]	D · CO		Feb 12, 2020
Rep. Kelly, Mike [R-PA-16]	R · PA		Feb 12, 2020
Rep. Marshall, Roger [R-KS-1]	R · KS		Feb 12, 2020
Rep. Mullin, Markwayne [R-OK-2]	R · OK		Feb 12, 2020
Rep. Schweikert, David [R-AZ-6]	R · AZ		Feb 12, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 12, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 4199	Related bill	Jul 2, 2020: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4228)
116 HR 19	Related bill	Dec 19, 2019: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
116 S 2543	Related bill	Sep 25, 2019: Placed on Senate Legislative Calendar under General Orders. Calendar No. 225.

Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act

This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.

Actions Timeline

- **Feb 12, 2020:** Introduced in House
- **Feb 12, 2020:** Referred to the House Committee on Energy and Commerce.